Apogee rises as long-acting eczema drug heads for phase 3 Apogee's chief executive Michael Henderson.

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis (AD), also known as eczema. Data from the REZOLVE-AD study ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

LOS ANGELES, CA, USA I July 14, 2025 I Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

What is eczema? How can you live better with it? Learn about treatments and ways to prevent itching and flares.

Learn home remedies and medical treatments to help ease your eczema symptoms and speed up your recovery.

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

No one will ever truly grasp the horrifying, never-ending ordeal,” Jada Jones told The Post. And it can happen to anyone.

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) soared 24% in Monday’s session following encouraging results from its Phase ...